BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common…Read More
Latest News CorMedix Inc Announces Pricing of 40 Million Public Businessfortnight
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/UXPLUUDBFVHPHHBW75IWXFDIBY.png)